FDA Approves New Drug Doubling Survival for Breast Cancer

Christina could barely walk last summer when her breast cancer returned and spread to her bones. Just weeks after starting a newly approved drug called datopotamab deruxtecan, the 33-year-old walked down the aisle as a bridesmaid at her sister-in-law's wedding.

Her story is becoming reality for thousands of people with triple-negative breast cancer, one of the hardest types to treat. The FDA approved the drug in May 2026 after clinical trials showed it doubled how long the cancer stayed under control and gave patients about six extra months of life compared to standard chemotherapy.

Triple-negative breast cancer affects up to 20% of breast cancer patients and has historically had few good treatment options. Unlike other breast cancers, these tumors lack three key markers that doctors normally target with drugs, leaving chemotherapy as the main option.

But datopotamab deruxtecan, or Dato-DXd, changes that calculation. The drug works like a smart bomb, seeking out cancer cells and delivering chemotherapy directly to them while sparing healthy tissue.

The results from the Tropion-Breast02 trial were remarkable. About 63% of patients saw their tumors measurably shrink, compared with just 29% on standard chemotherapy. The cancer stayed under control for nearly 11 months on average, compared with less than six months with chemotherapy alone.

Dr. Tiffany Traina, who led the U.S. arm of the trial at Memorial Sloan Kettering Cancer Center, calls it a major advance. "Having another targeted drug that is specifically approved for triple-negative disease is a major advance for patients," she says.

Christina started treatment at MSK in April 2026, getting access before the official FDA approval. "A few months ago, I was in a lot of pain," she says. "But thanks to this drug, I was recently able to walk down the aisle."

The Bright Side

Beyond just extending life, Dato-DXd improved how patients lived those extra months. Trial participants reported less pain and better ability to handle everyday activities. Fewer patients had to stop treatment due to side effects compared to those getting standard chemotherapy, even though common issues like mouth sores and fatigue still occurred.

The drug also represents a growing trend in cancer treatment. It's the latest in a series of targeted therapies approved specifically for triple-negative breast cancer in recent years, turning what was once a diagnosis with few options into one with increasing hope.

For Christina and her husband Kevin, that hope is everything. After being unable to work since her cancer spread, she's regaining the life she thought might slip away.

Thousands of patients with advanced triple-negative breast cancer now have access to a treatment that gives them not just more time, but better time.